Ingredion slashes earnings outlook on Argo plant disruption
Production failures and a thermal event at the Illinois sweetener facility forced the company to cut full-year guidance by five to seven percent.

Production failures and a thermal event at the Illinois sweetener facility forced the company to cut full-year guidance by five to seven percent.


Haleon Q1 2026 group organic revenue growth was 2.2%. Pain Relief came in essentially flat at -0.3% organic on £654m. Within Pain, Advil outperformed in North America driven by the No Pain More Gain campaign; Voltaren and Panadol grew in select geographies. Oral Health was the group-level standout. FY outlook reaffirmed.

Reckitt held Q1 2026 trading update on April 22, 2026 with Core LFL net revenue growth of 1.3% (3.1% excluding seasonal OTC). Emerging Markets grew 7.6% LFL to £1,087m. Mead Johnson Nutrition fell 2.7% LFL. FY 2026 guidance reaffirmed at 4 to 5% Core LFL. £1 billion share buyback continues with £669m completed by April 17.

Mondelez held Q1 2026 results on April 29 with 6.3% organic group growth (developed markets at 0.8%). CEO Van de Put characterized European consumer confidence as stable but fragile. Cocoa cost partially offset top-line, but the mid-year crop is described as quite positive. FY 2026 guidance reaffirmed at flat to +2% topline.

FY 2025 sales of €27.3 billion, up 4.5% like-for-like. Volume/mix +2.7% finally outpaces pricing +1.8%, the first European data point showing the mix engine has taken over from the rate engine.